Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Large Institutional Owners Must Be Happy as Stock Continues to Impress, up 10% Over the Past Week
Key Insights Given the large stake in the stock by institutions, Y-mAbs Therapeutics' stock price might be vulnerable to their trading decisions A total of 9 investors have a majority stake in the
We're Not Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn
Express News | Y-mAbs Therapeutics Inc : Jonestrading Initiates Coverage With Buy Rating; Target Price $23
JonesTrading Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $23
JonesTrading analyst Justin Walsh initiates coverage on $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and sets the target price at $23.According to TipRanks data, the analyst has a success rate
MSC Industrial Direct, Radius Recycling And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading lower this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects MSC Industrial Direct Co., Inc. (NYSE:MSM) to re
Y-Mabs Therapeutics Welcomes New CFO Amid Strategic Shift
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
PDF Version NEW YORK, July 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the developme
Express News | Y-mAbs Therapeutics Inc - Under Agreement of Settlement Co Has Agreed to Cause to Be Paid $19.7 Mln
Y-mAbs Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/28/2024 70.32% Truist Securities → $21 Initiates Coverage On → Buy 05/13/2024 78.43% HC Wainwright & Co
Express News | Y-mAbs Therapeutics Inc : Truist Securities Initiates Coverage With Buy Rating; Target Price $21
Truist Financial Initiates Y-mAbs Therapeutics(YMAB.US) With Buy Rating, Announces Target Price $21
Truist Financial analyst Nicole Germino initiates coverage on $Y-mAbs Therapeutics(YMAB.US)$ with a buy rating, and sets the target price at $21.According to TipRanks data, the analyst has a success r
Have Y-mAbs Therapeutics Insiders Been Selling Stock?
Some Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) shareholders may be a little concerned to see that the Founder, Thomas Gad, recently sold a substantial US$841k worth of stock at a price of US$12.02 per s
Y-mAbs Therapeutics(YMAB.US) Director Sells US$8,664 in Common Stock
$Y-mAbs Therapeutics(YMAB.US)$ Director Ber Gerard sold 722 shares of common stock on Jun 10, 2024 at an average price of $12 for a total value of $8,664.Source: Announcement What is statement of chan
Y-mAbs Therapeutics(YMAB.US) Officer Sells US$841.05K in Common Stock
$Y-mAbs Therapeutics(YMAB.US)$ Officer Gad Thomas sold 70,000 shares of common stock on Jun 10, 11, 2024 at an average price of $12.02 for a total value of $841.05K.Source: Announcement What is statem
Form 144 | Y-mAbs Therapeutics(YMAB.US) Officer Proposes to Sell 838.6K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 10, $Y-mAbs Therapeutics(YMAB.US)$ Officer Thomas Gad intends to sell 70,000 shares of its common stock on Jun 10, with a total market value of approximately $838.6K. Tho
With 43% Stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Seems to Have Captured Institutional Investors' Interest
Express News | Y-MAbs Therapeutics Says Preclinical GD2-SADA Data Will Be Presented At Society Of Nuclear Medicine & Molecular Imaging 2024 Annual Meeting
Y-mAbs Announces Preclinical GD2-SADA Data to Be Presented at 2024 SNMMI Annual Meeting
PDF Version NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the developme
Little Excitement Around Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues As Shares Take 30% Pounding
The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) share price has fared very poorly over the last month, falling by a substantial 30%. Still, a bad month hasn't completely ruined the past year with the s
Express News | Y-mAbs Deepens Radiopharmaceutical Leadership With Appointment of Norman Lafrance, M.d. as Chief Development Officer